Lokivetmab
Lokivetmab is a monoclonal antibody used in veterinary medicine for the treatment of canine atopic dermatitis. It is marketed under the trade name Cytopoint by Zoetis, a global animal health company.
Mechanism of Action[edit | edit source]
Lokivetmab works by targeting and neutralizing interleukin-31 (IL-31), a protein that sends itch signals to the brain. By blocking IL-31, Lokivetmab helps to reduce the itchiness and inflammation associated with atopic dermatitis.
Usage[edit | edit source]
Lokivetmab is administered by subcutaneous injection and can provide relief from itching for 4 to 8 weeks. The dosage and frequency of administration depend on the dog's weight and the severity of the symptoms.
Side Effects[edit | edit source]
The most common side effects of Lokivetmab include vomiting, diarrhea, lethargy, and decreased appetite. In rare cases, hypersensitivity reactions may occur.
Regulatory Status[edit | edit source]
Lokivetmab was approved by the European Medicines Agency (EMA) in 2017 and by the United States Food and Drug Administration (FDA) in 2016.
See Also[edit | edit source]
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD